For the Inventor, By the Inventor

Enter assignee name

Palo Alto, CA, United States of America

Syntex (u.s.a.) Inc.

USPTO Granted Patents = 932

Trademarks = 23

Forward Citations = 19,621

Loading Chart...

Loading Chart...

668 inventors (with patents filed for the assignee):

Edwin F Ullman (65 out of 199 patents)

Robin D Clark (49 out of 74 patents)

Joseph M Muchowski (49 out of 53 patents)

4. Peter H Nelson (42 out of 53 patents)

5. Keith Adrian Walker (38 out of 42 patents)

6. Colin C Beard (35 out of 36 patents)

7. John H Fried (30 out of 46 patents)

8. Brian H Vickery (28 out of 33 patents)

9. Jurg R Pfister (26 out of 43 patents)

10. Eric Brian Sjogren (26 out of 64 patents)

11. Gordon H Jones (26 out of 28 patents)

12. Karl G Untch (26 out of 26 patents)

13. Arthur F Kluge (23 out of 95 patents)

14. Michael C Venuti (23 out of 25 patents)

15. Denis John Kertesz (22 out of 29 patents)

Core Competencies:

Antiinflammation Agents

Muscarinic Receptor Antagonists

Nerve Growth Factor

Glycosyl Sulfotransferases

Adrenergic Receptor Antagonists

Calcium Channel Variants

Prostaglandin Analogues

CRF Antagonists

p38 MAP Kinase Inhibitors

Retinoid Compounds

HCV RNA Replication Inhibitors

Peptidic Procollagen C-Proteinase Inhibitors

932 patents: Sort by Forward Citations

1. 7186841 - Antiinflammation agents (2007-03-06),

2. 7141365 - Methods for diagnosing a mucin production associated disease condition (2006-11-28),

3. 7122325 - Method of modulating tetrotodoxin-resistant sodium channel (2006-10-17),

4. 7094778 - Heterocyclylalkylamines as muscarinic receptor antagonists (2006-08-22),

5. 7094591 - Human aggrecanase and nucleic acid compositions encoding the same (2006-08-22),

6. 7091200 - Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists (2006-08-15),

7. 7074763 - Stable formulations of nerve growth factor (2006-07-11),

8. 7071177 - P-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents (2006-07-04),

9. 7070971 - Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 (2006-07-04),

10. 7056903 - Carboxylic acid derivatives as IP antagonists (2006-06-06),

11. 7053103 - Ring fused pyrazole derivatives as CRF antagonists (2006-05-30),

12. 7049325 - Quinoline derivatives as anti-inflammatory agents (2006-05-23),

13. 7049317 - CCR-3 receptor antagonists (2006-05-23),

14. 7019007 - CCR-3 receptor antagonists (I) (2006-03-28),

15. 6984637 - Cyclic amine derivatives-CCR-3 receptor antagonists (2006-01-10),

Syntex (U.S.A.) Inc. is a leading pharmaceutical company specializing in the development and manufacturing of innovative healthcare solutions. With a strong focus on research and development, Syntex has successfully brought numerous life-saving drugs to market. Our mission is to improve the quality of human life by providing safe and effective medications. Visit our website for more information and explore our extensive range of products.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

932 Patents

#8 in Palo Alto, CA

#133 in California

#536 in US

#1,063 in the World

Palo Alto, CA, United States of America

Syntex (u.s.a.) Inc.

Forward Citations = 19,621

668 inventors:

Edwin F Ullman (65 out of 199 patents)

Robin D Clark (49 out of 74 patents)

Joseph M Muchowski (49 out of 53 patents)

4. Peter H Nelson (42 out of 53 patents)

5. Keith Adrian Walker (38 out of 42 patents)

Please report any incorrect information to support@idiyas.com

Loading…